Adverse Events After Routine Immunization of Extremely Low-Birth-Weight Infants

Stephen D DeMeo1, Sudha R Raman2, Christoph P Hornik3

  • 1Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.

JAMA Pediatrics
|June 2, 2015
PubMed

Insights

Immunization in extremely low-birth-weight (ELBW) infants is linked to more sepsis evaluations and respiratory support needs. Combination vaccines appear safe for ELBW infants, but further research is needed on timing and sepsis history.

Area of Science:

  • Neonatal Medicine
  • Pediatric Immunology
  • Vaccinology

Background:

  • Immunization in extremely low-birth-weight (ELBW) infants within neonatal intensive care units (NICUs) can lead to adverse events like fever and apnea.
  • These events create diagnostic challenges, potentially causing delayed immunizations and unnecessary sepsis evaluations.

Purpose of the Study:

  • To compare the incidence of sepsis evaluations, increased respiratory support, intubation, seizures, and mortality in ELBW infants within the 3 days before and after immunization.

Main Methods:

  • A multicenter retrospective cohort study involving 13,926 ELBW infants (born at ≤28 weeks gestation) across 348 NICUs.
  • Data collected from January 1, 2007, to December 31, 2012, focusing on infants receiving at least one immunization between 53 and 110 days of age.

Main Results:

  • Sepsis evaluations increased significantly post-immunization (5.4 to 19.3 per 1000 patient-days).
  • Increased respiratory support (6.6 to 14.0) and intubation rates (2.0 to 3.6) also rose post-immunization.
  • Incidence of adverse events was similar for combination vs. single vaccines; infants born at 23-24 weeks gestation and those with prior sepsis had higher risks.

Conclusions:

  • Routine immunization in ELBW infants is associated with increased sepsis evaluations, respiratory support, and intubation.
  • Current findings support the use of combination vaccines in ELBW infants.
  • Further research is warranted to explore the impact of immunization timing, spacing, and prior sepsis history on adverse events.
Abstract

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
54.6K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.3K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
1.2K
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...
238
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum...
202
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K